cbdMD, Inc.YCBDNYSE
Loading
cbdMD operates as a specialty cannabidiol (CBD) products manufacturer and direct-to-consumer retailer, selling topicals, tinctures, gummies, and pet products through e-commerce and retail partnerships. The company competes in the fragmented CBD wellness market with limited brand differentiation, facing significant cash burn and operational challenges evidenced by negative operating cash flow and a 79% one-year stock decline. With near-zero market cap and deteriorating liquidity metrics (0.00 current ratio), the company faces existential financial stress despite recent margin improvements.
cbdMD generates revenue through branded CBD product sales with 56.5% gross margins, suggesting moderate pricing power in a commoditized market. The business model relies on direct-to-consumer channels to capture higher margins versus wholesale, but faces customer acquisition costs that drive negative operating margins of -11.3%. Limited barriers to entry and regulatory uncertainty around CBD products constrain sustainable competitive advantages. The company lacks proprietary extraction technology or exclusive supply agreements that would differentiate it from hundreds of CBD competitors.
Federal regulatory developments on CBD classification and FDA enforcement actions affecting market legitimacy
Monthly e-commerce sales trends and customer acquisition cost efficiency metrics
Cash runway announcements and financing activities given negative operating cash flow
Retail partnership expansions with major pharmacy or grocery chains
Competitive pricing pressure from larger CPG entrants and private label CBD products
FDA regulatory uncertainty around CBD product claims, labeling requirements, and potential reclassification that could restrict sales channels or require costly compliance
Market commoditization as major CPG companies (Procter & Gamble, Unilever) and pharmaceutical firms enter CBD space with superior distribution and brand equity
Scientific evidence gaps regarding CBD efficacy for marketed wellness claims, risking consumer disillusionment and category contraction
Intense competition from 1,000+ CBD brands with minimal product differentiation and no proprietary formulations or patents
Amazon's potential entry into CBD sales would devastate direct-to-consumer economics and customer acquisition strategies
Private label CBD products from major retailers (CVS, Walgreens, Walmart) offering lower prices with comparable quality perception
Critical liquidity crisis evidenced by 0.00 current ratio and negative operating cash flow requiring immediate capital raise or bankruptcy risk
Negative ROE of -14.5% and ROA of 0.0% indicating value destruction and inability to generate returns on invested capital
Going concern risk given cash burn rate, minimal market cap, and 79% one-year stock decline suggesting investor abandonment
high - CBD wellness products are discretionary purchases that correlate strongly with consumer confidence and disposable income. During economic downturns, consumers reduce spending on non-essential supplements and wellness products. The company's negative cash flow position makes it particularly vulnerable to demand shocks that would further compress already-negative operating margins.
Rising interest rates negatively impact cbdMD through multiple channels: higher discount rates compress valuation multiples for unprofitable growth companies, increased borrowing costs strain already-negative cash flow, and reduced consumer discretionary spending from mortgage/credit costs. The company's distressed financial position limits access to capital markets, making rate increases particularly damaging.
High exposure to credit conditions. With 0.00 current ratio and negative operating cash flow, the company requires external financing to continue operations. Tightening credit markets or risk-off sentiment among lenders would severely constrain liquidity options. The low debt/equity ratio of 0.07 suggests limited existing debt capacity but also indicates difficulty accessing credit markets given operational losses.
momentum - The stock attracts speculative retail traders betting on short-term regulatory catalysts or acquisition rumors, evidenced by 29% three-month return despite deteriorating fundamentals. The 79% one-year decline and near-zero market cap indicate this is a distressed situation with binary outcomes (restructuring/acquisition versus bankruptcy), appealing only to high-risk speculators rather than institutional investors.
high - Micro-cap stock with minimal liquidity, negative cash flow, and binary regulatory/financing outcomes creates extreme volatility. The divergence between recent 29% three-month gain and 79% one-year loss demonstrates erratic price action driven by sentiment rather than fundamentals. Beta likely exceeds 2.0 relative to broader market.